Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 13 points (-0.1%) at 18,461 as of Wednesday, July 27, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,210 issues advancing vs. 1,692 declining with 152 unchanged.

The Health Care sector currently sits up 1.4% versus the S&P 500, which is down 0.3%. Top gainers within the sector include

Illumina

(

ILMN

), up 7.8%,

Seattle Genetics

(

SGEN

), up 6.5%,

Regeneron Pharmaceuticals

(

REGN

), up 2.6%,

Celgene

(

CELG

), up 2.0% and

Allergan

(

AGN

), up 1.3%. On the negative front, top decliners within the sector include

Globus Medical

(

GMED

), down 13.9%,

Universal Health Services

(

UHS

), down 5.6%,

Acadia Healthcare

(

ACHC

), down 4.9%,

C.R. Bard

(

BCR

), down 4.1% and

Quintiles Transnational Holdings

(

Q

), down 3.7%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

GlaxoSmithKline

(

GSK

) is one of the companies pushing the Health Care sector higher today. As of noon trading, GlaxoSmithKline is up $0.72 (1.6%) to $44.88 on heavy volume. Thus far, 4.0 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $44.79-$45.13 after having opened the day at $44.91 as compared to the previous trading day's close of $44.16.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $107.2 billion and is part of the drugs industry. Shares are up 9.4% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate GlaxoSmithKline a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

GlaxoSmithKline

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and generally higher debt management risk. Get the full

GlaxoSmithKline Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

AstraZeneca

(

AZN

) is up $0.30 (0.9%) to $31.20 on heavy volume. Thus far, 5.6 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $31.04-$31.39 after having opened the day at $31.05 as compared to the previous trading day's close of $30.91.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. AstraZeneca has a market cap of $78.8 billion and is part of the drugs industry. Shares are down 8.9% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates AstraZeneca a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Edwards Lifesciences

(

EW

) is up $7.05 (6.5%) to $115.40 on heavy volume. Thus far, 3.1 million shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $114.01-$117.46 after having opened the day at $116.15 as compared to the previous trading day's close of $108.35.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $22.6 billion and is part of the health services industry. Shares are up 37.2% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Edwards Lifesciences

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Edwards Lifesciences Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).